Comparative Pharmacology
Head-to-head clinical analysis: JANIMINE versus PROTRIPTYLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANIMINE versus PROTRIPTYLINE HYDROCHLORIDE.
JANIMINE vs PROTRIPTYLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imipramine inhibits the reuptake of norepinephrine and serotonin at nerve terminals, potentiating their neurotransmission. It also has anticholinergic and antihistaminergic effects.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft. May also downregulate beta-adrenergic and serotonin receptors.
25-50 mg orally 2-4 times daily; maintenance 150 mg/day divided
15 mg orally 3 to 4 times daily, not to exceed 60 mg per day.
None Documented
None Documented
5-15 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for steady state.
Terminal elimination half-life: 54-92 hours (mean ~74 hours); due to long half-life, steady-state is reached in 11-18 days.
Primarily renal (70-80% as metabolites, 5% unchanged); biliary/fecal (20-30% as metabolites).
Primarily renal (50-70% as metabolites, <5% unchanged); biliary/fecal elimination accounts for ~10-20%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant